Lymph node involvement influenced by lung adenocarcinoma subtypes in tumor size ≤3 cm disease: A study of 2268 cases

European Journal of Surgical Oncology

Volumn 42, Issue 11, 2016, Pages 1714-1719

  Yu, Y ^a   Jian, H ^a   Shen, L ^a   Zhu, L ^a   Lu, S ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Histologic classification; Lung adenocarcinoma; Lymph node involvement

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ACINAR CELL CARCINOMA; ADENOCARCINOMA; ADENOCARCINOMA IN SITU; ADULT; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LOBECTOMY; LUNG ADENOCARCINOMA; LYMPH NODE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAPILLARY CARCINOMA; PRIORITY JOURNAL; AGED; GENETICS; LUNG TUMOR; MUTATION; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84962570733     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2016.02.247     Document Type: Article

References (20)

1. 1 Jemal, A., Bray, F., Center, M.M., et al. Global cancer statistics. CA Cancer J Clin 61 (2011), 69–90.
2. 2 Goldstraw, P., Crowley, J., Chansky, K., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2 (2007), 706–714.
3. 3 Haruki, T., Aokage, K., Miyoshi, T., et al. Mediastinal nodal involvement in patients with clinical stage I non-small-cell lung cancer: possibility of rational lymph node dissection. J Thorac Oncol 10 (2015), 930–936.
4. 4 Mimae, T., Tsutani, Y., Miyata, Y., et al. Role of lymphatic invasion in the prognosis of patients with clinical node-negative and pathologic node-positive lung adenocarcinoma. J Thorac Cardiovasc Surg 147 (2014), 1820–1826.
5. 5 Travis, W.D., Brambilla, E., Noguchi, M., et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6 (2011), 244–285.
6. 6 Travis, W.D., Brambilla, E., Nicholson, A.G., et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10 (2015), 1243–1260.
7. 7 Hung, J.J., Yeh, Y.C., Jeng, W.J., et al. The previous reports showed that the IASLC/ATS/ERS classification of lung adenocarcinoma has significant prognostic and predictive value regarding death and recurrence. J Clin Oncol 32 (2014), 2357–2364.
8. 8 Zhang, J., Wu, J., Tan, Q., et al. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol 8 (2013), 1196–1202.
9. 9 Yoshizawa, A., Motoi, N., Riely, G.J., et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24 (2011), 653–664.
10. 10 Warth, A., Muley, T., Meister, M., et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30 (2012), 1438–1446.
11. 11 Russell, P.A., Wainer, Z., Wright, G.M., Daniels, M., Conron, M., Williams, R.A., Does lung adenocarcinoma subtype predict patient survival?: a clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 6 (2011), 1496–1504.
12. 12 Yoshizawa, A., Sumiyoshi, S., Sonobe, M., et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Onco 8 (2013), 52–61.
13. 13 Eguchi, T., Kadota, K., Park, B.J., et al. The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg 26 (2014), 210–222.
14. 14 Landreneau, R.J., Normolle, D.P., Christie, N.A., et al. Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis. J Clin Oncol 32 (2014), 2449–2455.
15. 15 Chang, J.Y., Senan, S., Paul, M.A., et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16 (2015), 630–637.
16. 16 Rami-Porta, R., Bolejack, V., Crowley, J., et al. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 10 (2015), 990–1003.
17. 17 Baba, T., Uramoto, H., Kuwata, T., et al. A study of surgically resected peripheral non-small cell lung cancer with a tumor diameter of 1.0 cm or less. Scand J Surg 100 (2011), 153–158.
18. 18 Shi, C.L., Zhang, X.Y., Han, B.H., He, W.Z., Shen, J., Chu, T.Q., A clinicopathological study of resected non-small cell lung cancers 2 cm or less in diameter: a prognostic assessment. Med Oncol 28 (2011), 1441–1446.
19. 19 Yeh, Y.C., Nitadori, J., Kadota, K., et al. Micropapillary histology is associated with occult lymph node metastasis (pN2) in patients with clinically N2-negative (cN0/N1) lung adenocarcinoma. J Thorac Oncol, 8, 2013, S671.
20. 20 Liu, S., Wang, R., Zhang, Y., et al. Precise diagnosis of intraoperative frozen section is an effective method to guide resection strategy for peripheral small-sized lung adenocarcinoma. J Clin Oncol, 2015 Nov 23 pii: JCO634907. [Epub ahead of print].